Updated:
Transcode Therapeutics
TransCode Therapeutics is a clinical-stage company in the healthcare sector, focused on immuno-oncology and RNA therapeutics. The company develops targeted...
Transcode Therapeutics
TransCode Therapeutics is a clinical-stage company in the healthcare sector, focused on immuno-oncology and RNA therapeutics. The company develops targeted therapies, such as TTX-MC138, which targets microRNA-10b in metastatic cancer treatment. Founded in 2016, TransCode Therapeutics is based in Boston, Massachusetts, and utilizes its TTX iron oxide nanoparticle delivery platform.
General information
Firm type
other
Frequently asked questions
Who runs investment decisions at Transcode Therapeutics?
Transcode Therapeutics is a publicly traded biotechnology company, not a family office or investment firm. Investment decisions are made by its board of directors and management team, whose names are disclosed in SEC filings.
How does Transcode source proprietary deal flow?
Transcode develops its own pipeline of siRNA therapeutics internally. The company has not disclosed any in-licensing or partnering activity for its core platform.
Is Transcode structured as a single family office or does it operate more like a venture firm?
Transcode is a publicly traded biotechnology company listed on Nasdaq under the symbol RNAZ. It is not structured as a family office or asset manager.
What investment stages does Transcode typically target?
Transcode does not make investments. It is a therapeutic developer targeting preclinical and clinical-stage development of its own drug candidates.
Which sectors does Transcode explicitly avoid?
Transcode focuses exclusively on RNA therapeutics for oncology and fibrosis. It does not operate in other therapeutic areas or asset classes.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: